Tirzepatide 30 mg Vial Dosage Protocol

Tirzepatide (30 mg Vial) Dosage Protocol

At a Glance

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that simultaneously activates both incretin pathways to suppress appetite, slow gastric emptying, and improve insulin sensitivity. The 30 mg vial follows the same once-weekly titration protocol as the 10 mg vial but at a higher concentration (10.0 mg/mL vs. 5.0 mg/mL), providing a more economical supply for longer cycles. In the SURMOUNT-1 trial, participants receiving tirzepatide achieved up to 22.5% mean body-weight reduction over 72 weeks.[1]

  • Reconstitute: Add 3.0 mL bacteriostatic water → 10.0 mg/mL concentration.
  • Starting dose: 2.5 mg once weekly (25 units / 0.25 mL) for the first 4 weeks.
  • Easy measuring: At 10.0 mg/mL on a U-100 syringe, 1 unit = 0.01 mL = 0.10 mg (100 mcg).
  • Note: Concentration is double the 10 mg vial (5.0 mg/mL) — volumes are smaller; measure carefully.
  • Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks.

How to Mix & Dose

Everything you need to reconstitute and dose Tirzepatide from a 30 mg vial

Dosing Schedule (3.0 mL → 10.0 mg/mL)

Weeks Dose Units (U-100) Volume
Weeks 1–4 (initiation) 2.5 mg 25 units 0.25 mL
Weeks 5–8 5 mg 50 units 0.50 mL
Weeks 9–12 7.5 mg 75 units 0.75 mL
Weeks 13–16 10 mg 100 units 1.00 mL
Weeks 17–20 12.5 mg 63 + 62 units × 2 injections 0.625 mL × 2
Weeks 21+ (maintenance) 15 mg 75 + 75 units × 2 injections 0.75 mL × 2

Frequency: Inject once weekly on the same day each week. For doses above 10 mg from a 10.0 mg/mL solution (i.e., volumes exceeding 1.0 mL), split into two separate subcutaneous injections at different sites. At 10.0 mg/mL, a 30 mg vial provides 3 doses at 10 mg, 6 doses at 5 mg, or 12 doses at 2.5 mg. Slow titration minimises nausea, vomiting, and diarrhoea — the most common adverse effects.[1]

How to Reconstitute

  1. Allow frozen lyophilised vial to reach room temperature (10–15 minutes).
  2. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the inner vial wall; do not inject directly onto the powder cake.
  4. Gently swirl or roll until fully dissolved — do not shake. Solution should be clear and colourless.
  5. Label with reconstitution date; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

What You’ll Need

Plan based on a 20-week titration (Wks 1–4: 2.5 mg; 5–8: 5 mg; 9–12: 7.5 mg; 13–16: 10 mg; 17–20: 12.5 mg). Total dose ≈ 160 mg over 20 weeks.

  • Tirzepatide Vials (30 mg each): 160 mg cumulative → 6 vials (vs. 16+ × 10 mg vials for the same cycle).
  • Insulin Syringes (U-100, 1 mL): 20 weekly injections, some split into 2 → 24–28 syringes.
  • Bacteriostatic Water (10 mL bottles): 3.0 mL per vial → 2 × 10 mL bottles covers all 6 vials.
  • Alcohol Swabs: 2 per injection → ≈ 56 swabs for the 20-week course.

Overview

  • Goal: Progressive weight loss and metabolic improvement via dual GIP/GLP-1 receptor agonism — appetite suppression, enhanced insulin sensitivity, and reduced caloric intake.[1]
  • Schedule: Once-weekly subcutaneous injection; dose escalated every 4 weeks.
  • Dose range: 2.5 mg (initiation) → 15 mg (maximum maintenance).
  • Reconstitution: 3.0 mL BAC water per 30 mg vial → 10.0 mg/mL.
  • Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

Dosing Details

  • Weeks 1–4: 2.5 mg (25 units / 0.25 mL) once weekly — initiation and tolerability.
  • Weeks 5–8: 5 mg (50 units / 0.50 mL) once weekly.
  • Weeks 9–12: 7.5 mg (75 units / 0.75 mL) once weekly.
  • Weeks 13–16: 10 mg (100 units / 1.00 mL) once weekly.[2]
  • Weeks 17–20: 12.5 mg (split: 63 + 62 units at different sites) once weekly.
  • Weeks 21+: 15 mg (split: 75 + 75 units at different sites) once weekly — maximum maintenance.

Storage

  • Lyophilised: Store at −20 °C (−4 °F) or below; protect from moisture and light.
  • Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
  • Appearance: Clear and colourless. Discard if cloudy, coloured, or particulate.

Good to Know

  • The 30 mg vial at 10.0 mg/mL is double the concentration of the 10 mg vial (5.0 mg/mL) — draw volumes are half as large for the same dose. Take extra care when measuring.
  • Inject on the same day each week to maintain stable plasma levels (half-life ≈ 5 days).
  • If a dose is missed by ≤4 days, administer as soon as possible; otherwise skip and resume the next scheduled day.
  • Do not advance to the next dose tier if GI side effects are poorly tolerated — hold at the current dose for an additional 4 weeks.
  • For doses above 10 mg (i.e., >1.0 mL volume), always split into two separate subcutaneous injections at different sites on the same day.
  • Monitor blood glucose when used alongside other glucose-lowering agents.

How Tirzepatide Works

Tirzepatide is a 39-amino acid synthetic peptide featuring a C20 fatty diacid moiety that promotes albumin binding, extending its half-life to approximately 5 days and enabling once-weekly dosing. Unlike pure GLP-1 agonists such as semaglutide, tirzepatide simultaneously activates both the GIP and GLP-1 receptors, producing synergistic metabolic effects.[1]

GIP receptor activation enhances pancreatic beta-cell insulin secretion in a glucose-dependent manner and promotes lipid metabolism in adipose tissue. GLP-1 receptor activation suppresses appetite centrally, slows gastric emptying, and inhibits glucagon secretion. The dual-agonist mechanism delivers greater insulin sensitivity improvement and more pronounced weight loss compared to selective GLP-1 receptor agonists alone, as demonstrated in head-to-head trials.[2] The 30 mg vial format does not alter the pharmacology — it simply provides a higher-concentration supply suited to longer continuous research cycles extending to the 12.5–15 mg maintenance tiers.

Benefits & What to Watch For

  • Weight reduction: SURMOUNT-1 (n=2,539): up to 22.5% mean weight loss at 72 weeks with 15 mg/week tirzepatide vs. 3.1% placebo.[1]
  • Glycaemic control: SURPASS-2 demonstrated superior HbA1c reductions compared to semaglutide 1 mg, with additional benefit at higher tirzepatide doses.[2]
  • Insulin sensitivity: Dual GIP/GLP-1 agonism improves whole-body insulin sensitivity to a greater degree than GLP-1 agonism alone.
  • GI side effects: Nausea (up to 29%), diarrhoea (≈17%), vomiting (≈9%) — dose-dependent and typically transient; slow titration mitigates severity.
  • Concentration caution: At 10.0 mg/mL, dosing errors from miscounting syringe units carry a larger absolute dose consequence than at 5.0 mg/mL — double-check volumes before injecting.
  • Contraindications: Personal or family history of medullary thyroid carcinoma or MEN2 (boxed warning); history of pancreatitis warrants caution.

Tips for Best Results

  • Pair with a reduced-calorie diet and regular physical activity (both resistance and aerobic) to maximise fat loss while preserving lean mass.
  • Eat smaller, more frequent meals to minimise nausea — particularly during early titration phases.
  • Prioritise protein intake (1.2–1.6 g/kg/day) to counteract lean-mass loss during caloric deficit.
  • Stay well hydrated; GI side effects can increase dehydration risk.
  • Track weekly body weight, waist circumference, and fasting glucose to assess response across the longer 20+ week cycle this vial format supports.

Injection Tips

  • Clean vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully.
  • Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose.
  • Pinch a skin fold; insert needle at 45° into subcutaneous tissue (90° acceptable with short needles into a pinched fold).[CDC]
  • Inject slowly over 2–3 seconds; do not aspirate. Withdraw and apply gentle pressure.
  • For split doses (12.5 mg and 15 mg), use two separate syringes and two separate injection sites on the same day; do not combine both volumes into one syringe.
  • Rotate sites (abdomen, thighs, upper arms); dispose of each syringe in a sharps container immediately after use.

Important Note

This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. This peptide is not approved for human therapeutic use. For research use only. The 30 mg vial contains a higher concentration (10.0 mg/mL) than the 10 mg vial (5.0 mg/mL) — verify your reconstitution before measuring doses.

References


  • Jastreboff AM et al. — NEJM (2022) SURMOUNT-1 Trial — PMID 35658024
    Tirzepatide once weekly in adults with obesity: up to 22.5% mean weight loss vs. 3.1% placebo at 72 weeks across 2.5–15 mg dose range
    View Source

  • Frías JP et al. — NEJM (2021) SURPASS-2 Trial — PMID 34170647
    Tirzepatide vs. semaglutide 1 mg in type 2 diabetes: superior HbA1c reduction and weight loss at all three tirzepatide dose levels
    View Source

  • CDC — General Best Practice Guidelines for Immunization
    Subcutaneous injection technique, angle, and site rotation guidance
    View Source

Looking for research-grade Tirzepatide 30 mg? Our sponsor White Market Peptides carries Tirzepatide 30 mg with third-party purity testing. Use code PEPDOSE for 10% off + free 2-day shipping over $200.